These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35359635)

  • 1. Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab.
    Mancuso R; Agostini S; Hernis A; Caputo D; Galimberti D; Scarpini E; Clerici M
    Front Neurol; 2022; 13():819911. PubMed ID: 35359635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
    Meira M; Sievers C; Hoffmann F; Haghikia A; Rasenack M; Décard BF; Kuhle J; Derfuss T; Kappos L; Lindberg RL
    Neurol Neuroimmunol Neuroinflamm; 2016 Jun; 3(3):e223. PubMed ID: 27088119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
    Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
    Agostini S; Mancuso R; Costa AS; Caputo D; Clerici M
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33809082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication.
    Takahashi K; Sato Y; Sekizuka T; Kuroda M; Suzuki T; Hasegawa H; Katano H
    PLoS Pathog; 2020 Apr; 16(4):e1008523. PubMed ID: 32324824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy.
    Giovannelli I; Martelli F; Repice A; Massacesi L; Azzi A; Giannecchini S
    J Neurovirol; 2015 Dec; 21(6):666-70. PubMed ID: 25678142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
    Fissolo N; Pignolet B; Matute-Blanch C; Triviño JC; Miró B; Mota M; Perez-Hoyos S; Sanchez A; Vermersch P; Ruet A; de Sèze J; Labauge P; Vukusic S; Papeix C; Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Montalban X; Brassat D; Comabella M;
    Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-126: a novel route for natalizumab action?
    Meira M; Sievers C; Hoffmann F; Derfuss T; Kuhle J; Kappos L; Lindberg RL
    Mult Scler; 2014 Sep; 20(10):1363-70. PubMed ID: 24598267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
    Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
    Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
    Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
    Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
    Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
    PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
    Diotti RA; Mancini N; Clementi N; Sautto G; Moreno GJ; Criscuolo E; Cappelletti F; Man P; Forest E; Remy L; Giannecchini S; Clementi M; Burioni R
    Antiviral Res; 2014 Aug; 108():94-103. PubMed ID: 24909571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
    Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
    Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
    [No Abstract]   [Full Text] [Related]  

  • 17. Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
    Auer M; Bauer A; Oftring A; Rudzki D; Hegen H; Bsteh G; Di Pauli F; Berek K; Zinganell A; Berger T; Reindl M; Deisenhammer F
    CNS Drugs; 2022 Oct; 36(10):1121-1131. PubMed ID: 36173556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. John Cunningham Virus and Progressive Multifocal Leukoencephalopathy: A Falsely Played Diagnosis.
    Mouliou DS
    Diseases; 2024 May; 12(5):. PubMed ID: 38785755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML.
    Rocca A; Martelli F; Delbue S; Ferrante P; Bartolozzi D; Azzi A; Giannecchini S
    J Clin Virol; 2015 Sep; 70():1-6. PubMed ID: 26305810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.